Childhood Hematological Malignancies Training Program
儿童血液恶性肿瘤培训计划
基本信息
- 批准号:10456864
- 负责人:
- 金额:$ 28.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-08 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY/ABSTRACT
Hematological malignancies are the commonest childhood tumors, and despite remarkable advances in survival
rates, remain a leading cause of cancer death. The last decade has witnessed great progress in understanding
the genetic basis of these tumors, but translating these discoveries into mechanistic insight into the basis of
tumorigenesis and treatment response, and into new diagnostic and therapeutic approaches remains limited.
Advancing outcomes for children with hematologic malignancies is reliant on training independent investigators
with expertise in genomic analysis, experimental modeling, translational science and preclinical modeling of
childhood hematological malignancies. Although some T32 training program provide training in childhood cancer,
none are solely devoted to training in hematological malignancies or a training program that utilizes the rich
foundation of genomic discoveries from the Pediatric Cancer Genome Project. The proposed training program
will equip the next generation of scientists with the skills and knowledge from multiple disciplines to become
leaders in the field of childhood hematological malignancy research. The proposed program will train three
postdoctoral fellows in the first three years, and four fellows in years four and five, with an additional position
supported by St Jude. The program will provide an enriched training experience supported by faculty with diverse
expertise, including mentorship teams for each trainee consisting of scientific and clinical investigators; a T32
Internal Executive Committee that reviews program progress and assists with training program development and
coordination of training activities; an External Advisory Committee comprised of five national leaders in childhood
cancer research and postdoctoral training; a dedicated lecture/seminar series providing training in genomics,
genetics, pathology, biostatistics, experimental modeling, genome editing, immunotherapy, preclinical studies
and clinical trial design; a trainee day featuring trainee and invited speaker presentations; training in scientific
and grant writing; the requirement that trainees submit external grant funding applications no later than the
second year of the fellowship; and detailed evaluation of the progress of trainees. Trainees will be closely
integrated with the rich portfolio of basic to translational research activities of the St Jude Comprehensive Cancer
Center Hematological Malignancies Program, which coordinates translation of basic science discoveries to
clinical trials. This program will provide an unrivalled opportunity to train scientists to address critical unmet needs
in childhood hematological malignancies.
PROJECT SUMMARY/ABSTRACT
Hematological malignancies are the commonest childhood tumors, and despite remarkable advances in survival
rates, remain a leading cause of cancer death. The last decade has witnessed great progress in understanding
the genetic basis of these tumors, but translating these discoveries into mechanistic insight into the basis of
tumorigenesis and treatment response, and into new diagnostic and therapeutic approaches remains limited.
Advancing outcomes for children with hematologic malignancies is reliant on training independent investigators
with expertise in genomic analysis, experimental modeling, translational science and preclinical modeling of
childhood hematological malignancies. Although some T32 training program provide training in childhood cancer,
none are solely devoted to training in hematological malignancies or a training program that utilizes the rich
foundation of genomic discoveries from the Pediatric Cancer Genome Project. The proposed training program
will equip the next generation of scientists with the skills and knowledge from multiple disciplines to become
leaders in the field of childhood hematological malignancy research. The proposed program will train three
postdoctoral fellows in the first three years, and four fellows in years four and five, with an additional position
supported by St Jude. The program will provide an enriched training experience supported by faculty with diverse
expertise, including mentorship teams for each trainee consisting of scientific and clinical investigators; a T32
Internal Executive Committee that reviews program progress and assists with training program development and
coordination of training activities; an External Advisory Committee comprised of five national leaders in childhood
cancer research and postdoctoral training; a dedicated lecture/seminar series providing training in genomics,
genetics, pathology, biostatistics, experimental modeling, genome editing, immunotherapy, preclinical studies
and clinical trial design; a trainee day featuring trainee and invited speaker presentations; training in scientific
and grant writing; the requirement that trainees submit external grant funding applications no later than the
second year of the fellowship; and detailed evaluation of the progress of trainees. Trainees will be closely
integrated with the rich portfolio of basic to translational research activities of the St Jude Comprehensive Cancer
Center Hematological Malignancies Program, which coordinates translation of basic science discoveries to
clinical trials. This program will provide an unrivalled opportunity to train scientists to address critical unmet needs
in childhood hematological malignancies.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles G. Mullighan其他文献
Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131
- DOI:
10.1182/blood-2023-190495 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Wanda L. Salzer;Michael J. Burke;Meenakshi Devidas;Zhiguo (Bruce) Chen;Michael J. Borowitz;Andrew J Carroll;I-Ming L. Chen;Julie M. Gastier-Foster;Richard C. Harvey;Nyla A. Heerema;Charles G. Mullighan;Karen R. Rabin;Shalini C Reshmi;Cheryl L. Willman;Brent L. Wood;Naomi J. Winick;William L. Carroll;Elizabeth A. Raetz;Mignon L. Loh;Stephen P. Hunger - 通讯作者:
Stephen P. Hunger
Prior Knowledge Integration Improves Relapse Prediction and Identifies Relapse Associated Mechanisms in Childhood B Cell Acute Lymphoblastic Leukemia
- DOI:
10.1182/blood-2023-187264 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Abhishek Vallabhbhai Koladiya;Astraea Jager;Anthony Culos;Milton Merchant;Yuxuan Liu;Lucille Stuani;Jolanda Sarno;Pablo Domizi;Charles G. Mullighan;Nima Aghaeepour;Sean Bendall;Kara L. Davis - 通讯作者:
Kara L. Davis
Human Models of emNUP98/em-Rearranged Leukemia Reveal Fusion-Specific Molecular Mechanisms
- DOI:
10.1182/blood-2022-164686 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:23.100
- 作者:
Masayuki Umeda;Nicole L. Michmerhuizen;Ryan Hiltenbrand;Juan M. Barajas;Bright Arthur;Sherif Abdelhamed;Jing Ma;Tamara Westover;Jonathan Miller;Charles G. Mullighan;Jeffery M. Klco - 通讯作者:
Jeffery M. Klco
The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia
- DOI:
10.1182/blood-2023-181788 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Satoshi Yoshimura;Zhenhua Li;Yoshihiro Gocho;Wenjian Yang;Kristine R Crews;Shawn H.R. Lee;Kathryn G. Roberts;Charles G. Mullighan;Mary V. Relling;Federico Antillon-Klussmann;Allen Eng Juh Yeoh;Mignon L. Loh;Mark R. Litzow;Sima Jeha;Seth E. Karol;Hiroto Inaba;Ching-Hon Pui;Marina Y. Konopleva;Nitin Jain;Wendy Stock - 通讯作者:
Wendy Stock
Genetic and Functional Characterization of <em>NUP98</em>-Rearranged Leukemia
- DOI:
10.1182/blood-2024-210208 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Masayuki Umeda;Nicole L Michmerhuizen;Ryan Hiltenbrand;Juan M Barajas;Bright Arthur;Michael P Walsh;Guangchun Song;Jing Ma;Tamara Westover;Petri Pölönen;Cristina Mecucci;Danika Di Giacomo;Franco Locatelli;Riccardo Masetti;Salvatore Bertuccio;Martina Pigazzi;Ilaria Iacobucci;Charles G. Mullighan;Jeffery M Klco - 通讯作者:
Jeffery M Klco
Charles G. Mullighan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles G. Mullighan', 18)}}的其他基金
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
- 批准号:
10829603 - 财政年份:2023
- 资助金额:
$ 28.95万 - 项目类别:
Childhood Hematological Malignancies Training Program
儿童血液恶性肿瘤培训计划
- 批准号:
10226110 - 财政年份:2019
- 资助金额:
$ 28.95万 - 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
- 批准号:
10228882 - 财政年份:2019
- 资助金额:
$ 28.95万 - 项目类别:
相似海外基金
Analysis of dendritic cells from patients with hematologic neoplasms
血液肿瘤患者树突状细胞的分析
- 批准号:
09671138 - 财政年份:1997
- 资助金额:
$ 28.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the mechanism involved in chromosomal translocations founded in hematologic neoplasms.
澄清血液肿瘤中发现的染色体易位涉及的机制。
- 批准号:
09671096 - 财政年份:1997
- 资助金额:
$ 28.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of immunoglobulin, T cell receptor and cytokine genes in hematologic neoplasms
血液肿瘤中免疫球蛋白、T细胞受体和细胞因子基因分析
- 批准号:
61480260 - 财政年份:1986
- 资助金额:
$ 28.95万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)